Synbiotics represent an increasingly sophisticated approach to microbiome-focused products by combining live microorganisms with substrates designed to support beneficial microbial activity. However, regulatory classification and evidence requirements are becoming more complex as scientific understanding evolves. This article explains the difference between complementary and synergistic synbiotics, why the distinction matters for product development and health claims, and the clinical and regulatory considerations manufacturers must address. It also examines product characterization, clinical trial design, substantiation strategies, and the evolving expectations shaping the development and commercialization of synbiotic products across food, dietary supplement, and Natural Health Product (NHP) frameworks.
The microbiome sector has evolved rapidly over the past two decades, moving from generalized probiotic supplementation toward increasingly sophisticated approaches designed to influence microbial activity, metabolite production, and host interactions more precisely. Synbiotics sit at the center of that evolution.
Although the term has existed since the mid-1990s, the scientific understanding of synbiotics has changed substantially in recent years. Early formulations were largely based on the idea that combining a probiotic with a prebiotic could improve the survival, activity or persistence of beneficial microorganisms within the gastrointestinal tract. More recent frameworks have shifted away from this simplistic formulation concept toward a more functional interpretation centered on selective microbial utilization and coordinated biological activity.
This distinction matters from both a scientific and regulatory perspective.
As microbiome-related product categories become more complex, regulators are increasingly focused on how these products are characterized, substantiated, and clinically evaluated. For synbiotics specifically, the central challenge is no longer whether live microorganisms and substrates can simply be combined, but whether the resulting formulation demonstrates a clinically meaningful and sufficiently substantiated health benefit. For synergistic synbiotics, the evidence must also demonstrate selective utilization of the substrate by the co-administered microorganism and support an effect attributable to their coordinated activity.
The original synbiotic concept was introduced in 1995 as a combination of a probiotic and a prebiotic intended to work synergistically within the host gastrointestinal tract. However, concerns gradually emerged that this definition was scientifically too narrow and did not adequately account for the complexity of host-microbe interactions or evolving microbiome science.
In response, the International Scientific Association for Probiotics and Prebiotics (ISAPP) convened an expert panel that ultimately proposed a revised definition:
“A mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host.”
Importantly, the revised framework clarified that synbiotics are not always simply “probiotic + prebiotic” combinations. In a complementary synbiotic, both components must independently meet the accepted criteria for a probiotic and a prebiotic. In a synergistic synbiotic, neither component necessarily needs to qualify independently, provided that the substrate is selectively utilized by the co-administered microorganism and the combined formulation confers a demonstrated health benefit. This evolution reflects a broader shift occurring across microbiome science. Earlier approaches focused primarily on introducing beneficial organisms or stimulating microbial growth generally. More recent research increasingly examines targeted ecological interactions within the microbiome and how combinations of microorganisms and substrates may influence host physiology together.
Complementary and synergistic synbiotics
One of the most important aspects of the updated ISAPP framework is the distinction between complementary and synergistic synbiotics.
Complementary synbiotics
Complementary synbiotics combine:
Under this model, each component contributes separately to the overall effect.
However, evidence supporting the probiotic and prebiotic individually is not sufficient on its own. The combined formulation must also be tested and shown to confer a health benefit in the intended host. Otherwise, it should be described as a product containing a probiotic and a prebiotic rather than as a substantiated synbiotic.
This remains the most common commercial synbiotic approach because it aligns relatively well with existing probiotic and prebiotic evidence frameworks.
Synergistic synbiotics are more scientifically ambitious.
Under this model:
In this framework, neither component necessarily needs to independently satisfy probiotic or prebiotic criteria provided that the combined formulation demonstrates selective utilization and resulting health benefit.
This distinction has significant implications for scientific substantiation because synergistic synbiotics require evidence of both a health benefit and selective utilization of the substrate by the co-administered microorganism. ISAPP recommends demonstrating these outcomes in the same target-host study and showing that the combined effect is better than the estimated effects of the individual components.
The interest surrounding synbiotics reflects broader efforts to improve the consistency and functional impact of microbiome-targeted interventions.
Traditional probiotic products face several well-recognized challenges, including:
The rationale differs according to the type of synbiotic. In a synergistic synbiotic, the substrate is selected to support the growth or activity of the co-administered microorganism. In a complementary synbiotic, the probiotic and prebiotic may act independently, with the prebiotic primarily targeting members of the resident microbiota.
Research has explored synbiotic applications across a broad range of health areas, including:
The International Journal of Molecular Sciences review discussing postbiotics and related microbiome interventions also highlights how synbiotics may influence microbiota composition, microbial metabolite production, and immune interactions through coordinated microbial-substrate activity.
At the same time, the scientific literature remains highly heterogeneous.
Variability in:
continues to complicate interpretation and comparison across studies.
“Synbiotic” is primarily a scientific and commercial descriptor rather than a harmonized legal product category. Regulatory classification must therefore be determined under the existing framework of each jurisdiction based on the product’s ingredients, intended use, format and claims. Instead, classification depends heavily on:
Depending on the jurisdiction and positioning, a synbiotic product may be regulated as:
“Functional food” may be useful as a commercial description, but it is not a separate legal classification in every jurisdiction.
This becomes especially important where products move beyond generalized digestive health positioning into more targeted physiological or disease-related claims.
As microbiome categories expand, regulators are increasingly focused on evidentiary specificity rather than marketing terminology alone.
For synbiotics, this may include evaluating:
Whether the commercial formulation is comparable to the formulation used in supporting studies. The ISAPP framework itself emphasizes that demonstrating a synbiotic effect requires evidence supporting the combination, not simply evidence supporting individual ingredients separately.
As with probiotics, the quality of clinical substantiation is likely to become one of the primary differentiators within the synbiotic category.
The challenge is that microbiome-focused products often attempt to bridge mechanistic science with clinically meaningful outcomes, which can complicate study design substantially.
The appropriate study design depends on whether the product is intended to qualify as a complementary or synergistic synbiotic. Both require evidence that the combined formulation confers a health benefit, but the level and type of evidence differ. For a complementary synbiotic, a controlled study comparing the combined product with placebo may be sufficient because the probiotic and prebiotic components have already been independently established. A factorial or four-arm design is generally not necessary solely to establish complementary status.
For a synergistic synbiotic, the study should ordinarily include the microorganism alone, the substrate alone, the combined product and an appropriate control. This allows the researchers to demonstrate selective utilization and determine whether the combined effect exceeds the estimated effects of the individual components.
This often requires multi-arm study designs involving:
These requirements can increase trial complexity, statistical burden, and cost considerably.
Endpoint selection remains one of the most important considerations in microbiome-related clinical research.
dicentra’s earlier analysis of probiotic endpoints highlighted that many studies struggle because microbiome measurements alone are insufficient to support clinically meaningful claims.
This challenge becomes even more relevant for synbiotics.
Changes in:
may support mechanistic interpretation, but regulators generally expect clinically relevant outcomes tied to the intended product positioning.
For a synergistic synbiotic, the study should nevertheless include an appropriate microbiota or microbial-activity outcome to demonstrate selective utilization, alongside a clinically relevant health outcome. For a complementary synbiotic, selective utilization of the established prebiotic does not necessarily need to be reconfirmed in the final combination trial. As a result, synbiotic studies increasingly require careful alignment between:
Placebo design presents another important challenge in microbiome studies.
As dicentra previously discussed in relation to probiotic clinical trials, seemingly inert controls may still influence microbial fermentation, gastrointestinal physiology, or microbiota composition.
For synbiotics, placebo complexity increases further because:
ISAPP recommends that placebo selection reflect the intended comparison. For capsules or sachets, a low dose of a highly digestible ingredient or slowly fermentable fibre may be appropriate. For food or beverage interventions, differences in flavour, texture and nutrient composition must also be considered. These considerations become especially important in food-based or beverage-based synbiotic interventions.
Synbiotic formulations also introduce unique manufacturing and stability considerations.
Because live microorganisms remain central to the category, manufacturers must maintain viability throughout:
At the same time, the substrate component may directly influence microbial activity, stability, or metabolic output.
Regulators and researchers increasingly expect characterization of:
Specifications demonstrating that the commercial product represents the clinically studied formulation. These requirements reflect a broader trend across microbiome products toward increasingly detailed product characterization and reproducibility expectations.
The synbiotic category is still evolving scientifically, commercially, and regulatorily.
Future development is likely to move toward more targeted microbiome modulation strategies involving:
At the same time, regulators will likely continue emphasizing evidence quality, product characterization, and clinically meaningful substantiation.
As microbiome science matures, generalized digestive wellness positioning may gradually give way to more defined and mechanism-driven product strategies.
For manufacturers, this will likely require increasingly sophisticated regulatory and clinical planning early in development.
At dicentra, we support organizations developing microbiome-focused products across probiotics, prebiotics, synbiotics, and emerging postbiotic technologies.
Synbiotic products introduce unique regulatory and clinical considerations that require coordinated scientific, clinical, and commercialization strategies.
We support organizations by:
As microbiome science continues to evolve, companies will increasingly require evidence frameworks capable of supporting clinically and regulatorily defensible product positioning.
Contact dicentra to discuss synbiotic regulatory strategy, clinical development, and microbiome product commercialization support.